

# Richard M Weinshilboum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4747028/publications.pdf>

Version: 2024-02-01

273  
papers

20,397  
citations

18482

62  
h-index

12272

133  
g-index

288  
all docs

288  
docs citations

288  
times ranked

17957  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anastrozole Regulates Fatty Acid Synthase in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 206-216.	4.1	4
2	Targeted Genotyping in Clinical Pharmacogenomics. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 253-261.	2.8	13
3	Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. <i>British Journal of Pharmacology</i> , 2022, , .	5.4	4
4	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1854-1862.	7.0	5
5	Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2022, 63, 1347-1358.	5.2	2
6	Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1296-1306.	4.7	6
7	Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	2.4	28
8	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2022, 12, 412.	2.5	7
9	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomics-Driven</scp> Machine Learning Approach. <i>Arthritis Care and Research</i> , 2022, 74, 879-888.	3.4	15
10	Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism. <i>Molecular Metabolism</i> , 2022, 63, 101534.	6.5	5
11	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	7.0	3
12	ERICH3: vesicular association and antidepressant treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 2415-2428.	7.9	17
13	TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 3122-3133.	7.9	17
14	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 549-559.	2.6	6
15	A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?. <i>Genetics in Medicine</i> , 2021, 23, 461-470.	2.4	34
16	Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 35-45.	2.4	3
17	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. <i>Translational Psychiatry</i> , 2021, 11, 153.	4.8	46
18	<i>SLCO1B1</i>: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function. <i>Drug Metabolism and Disposition</i> , 2021, 49, 395-404.	3.3	17

#	ARTICLE	IF	CITATIONS
19	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	7.0	7
20	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1038-1049.	4.7	5
21	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). <i>Npj Breast Cancer</i> , 2021, 7, 79.	5.2	5
22	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	48
23	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. <i>Neuropsychopharmacology</i> , 2021, 46, 2132-2139.	5.4	19
24	Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?. <i>Pharmacogenomics</i> , 2021, 22, 913-925.	1.3	1
25	TCF7L2 lncRNA: a link between bipolar disorder and body mass index through glucocorticoid signaling. <i>Molecular Psychiatry</i> , 2021, 26, 7454-7464.	7.9	16
26	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , 2021, 46, 1272-1282.	5.4	14
27	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. <i>Translational Psychiatry</i> , 2021, 11, 513.	4.8	20
28	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 1-9.	1.5	0
29	Chronic cortisol differentially impacts stem cell-derived astrocytes from major depressive disorder patients. <i>Translational Psychiatry</i> , 2021, 11, 608.	4.8	11
30	Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 662-670.	4.7	11
31	Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. <i>Genetics in Medicine</i> , 2020, 22, 475-486.	2.4	67
32	Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). <i>International Journal of Epidemiology</i> , 2020, 49, 23-24k.	1.9	34
33	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	4.1	36
34	Therapeutic potential of triterpenoid saponin anemoside B4 from <i>Pulsatilla chinensis</i> . <i>Pharmacological Research</i> , 2020, 160, 105079.	7.1	39
35	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	7.4	257
36	Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort. <i>PLoS ONE</i> , 2020, 15, e0233316.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Regulation of sister chromatid cohesion by nuclear PD-L1. <i>Cell Research</i> , 2020, 30, 590-601.	12.0	58
38	Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1233-1242.	4.7	14
39	Knowledge-guided analysis of "omics" data using the KnowEnG cloud platform. <i>PLoS Biology</i> , 2020, 18, e3000583.	5.6	34
40	<i>CYP2C9</i> and <i>CYP2C19</i>: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants. <i>Clinical and Translational Science</i> , 2020, 13, 727-742.	3.1	33
41	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor I±. <i>Clinical Cancer Research</i> , 2020, 26, 2986-2996.	7.0	17
42	Selective Serotonin Reuptake Inhibitor Pharmacogenomics: Mechanisms and Prediction. <i>Frontiers in Pharmacology</i> , 2020, 11, 614048.	3.5	10
43	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	1.0	10
44	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. <i>Translational Psychiatry</i> , 2019, 9, 173.	4.8	53
45	Artificial Intelligence and Pharmacogenomics. <i>Advances in Molecular Pathology</i> , 2019, 2, 111-118.	0.4	0
46	Pharmacogenomics in Practice. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 936-938.	4.7	9
47	Integration of machine learning and pharmacogenomic biomarkers for predicting response to antidepressant treatment: can computational intelligence be used to augment clinical assessments?. <i>Pharmacogenomics</i> , 2019, 20, 983-988.	1.3	9
48	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 926.	2.8	15
49	Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. <i>Molecular Psychiatry</i> , 2019, 24, 795-807.	7.9	64
50	The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer. <i>Cancer &amp; Metabolism</i> , 2019, 7, 1.	5.0	17
51	Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy. <i>American Journal of Roentgenology</i> , 2019, 213, 932-943.	2.2	15
52	Studying treatment resistance in depression using patient derived neurons in vitro. <i>Molecular Psychiatry</i> , 2019, 24, 775-775.	7.9	2
53	Catechol O-Methyltransferase Pharmacogenomics: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 281-283.	4.7	4
54	Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine Learning Approach With Multi-Trial Replication. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 855-865.	4.7	69

#	ARTICLE	IF	CITATIONS
55	Clopidogrel Pharmacogenetics. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007811.	3.9	139
56	Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. <i>Molecular Psychiatry</i> , 2019, 24, 808-818.	7.9	66
57	The lncRNA MIR2052HG regulates ER $\alpha$ levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. <i>Breast Cancer Research</i> , 2019, 21, 47.	5.0	36
58	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor $\alpha$ -positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 567-578.	2.5	6
59	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in <i>CYP2C9</i> and <i>CYP2C19</i> . <i>Drug Metabolism and Disposition</i> , 2019, 47, 425-435.	3.3	17
60	Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand-Dependent Gene Expression. <i>Drug Metabolism and Disposition</i> , 2019, 47, 983-994.	3.3	13
61	Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine. <i>Frontiers in Pharmacology</i> , 2019, 10, 1302.	3.5	32
62	Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer. <i>Pharmacogenetics and Genomics</i> , 2019, 29, 183-191.	1.5	0
63	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. <i>Journal of Affective Disorders</i> , 2019, 246, 62-68.	4.1	16
64	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
65	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between <i>SLC38A7</i> and <i>ALPPL2</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 219-227.	4.7	10
66	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. <i>Oncotarget</i> , 2019, 10, 3924-3930.	1.8	11
67	ERICH3 Characterization: Function in Vesicular Trafficking and Antidepressant Treatment Response. <i>FASEB Journal</i> , 2019, 33, 680.1.	0.5	0
68	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 778-786.	4.7	110
69	TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor $\kappa$ B p65: Single Nucleotide Polymorphism and Estrogen Dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 700-710.	2.5	9
70	Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. <i>Biochemical Pharmacology</i> , 2018, 152, 279-292.	4.4	35
71	Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 767-769.	4.7	7
72	Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. <i>Translational Psychiatry</i> , 2018, 8, 10.	4.8	59

#	ARTICLE	IF	CITATIONS
73	Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure. , 2018, , .		16
74	Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clinical Pharmacology and Therapeutics, 2018, 103, 243-252.	4.7	7
75	TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacology and Therapeutics, 2018, 104, 201-210.	4.7	27
76	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. Journal of Clinical Investigation, 2018, 128, 2376-2388.	8.2	134
77	The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases. International Journal of Molecular Sciences, 2018, 19, 3851.	4.1	161
78	Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenetics and Genomics, 2018, 28, 147-152.	1.5	4
79	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. Journal of Affective Disorders, 2018, 238, 1-7.	4.1	28
80	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology, 2018, 28, 945-954.	0.7	64
81	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. Frontiers in Pharmacology, 2018, 9, 158.	3.5	21
82	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 65.	2.6	38
83	Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. IEEE Computational Intelligence Magazine, 2018, 13, 20-31.	3.2	34
84	Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction. Drug Metabolism and Disposition, 2018, 46, 1372-1381.	3.3	11
85	SLCO1B1 genetic variation and hormone therapy in menopausal women. Menopause, 2018, 25, 877-882.	2.0	16
86	SNPs Outside Response Elements Impact Aryl Hydrocarbon Receptor (AHR) Binding and Gene Regulation: Genome-wide SNP-dependent Transcriptional Regulation. FASEB Journal, 2018, 32, 694.3.	0.5	0
87	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Research and Treatment, 2017, 164, 189-199.	2.5	17
88	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	61
89	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes. Npj Breast Cancer, 2017, 3, 30.	5.2	18
90	Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach. Journal of Psychiatric Research, 2017, 95, 208-212.	3.1	4

#	ARTICLE	IF	CITATIONS
91	Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clinic Proceedings, 2017, 92, 1711-1722.	3.0	156
92	TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor- $\kappa$ B Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response. Molecular Pharmacology, 2017, 92, 175-184.	2.3	18
93	Multidisciplinary model to implement pharmacogenomics at the point of care. Genetics in Medicine, 2017, 19, 421-429.	2.4	74
94	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nature Reviews Drug Discovery, 2017, 16, 70-70.	46.4	80
95	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods. , 2017, , .		7
96	Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion. Breast Cancer Research, 2017, 19, 95.	5.0	22
97	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Research, 2017, 19, 130.	5.0	53
98	SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ER $\pm$ -positive breast cancer through regulation of BRCA1. PLoS Genetics, 2017, 13, e1007031.	3.5	22
99	Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer. Oncotarget, 2017, 8, 27199-27215.	1.8	15
100	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. Oncotarget, 2017, 8, 78133-78143.	1.8	6
101	Immune Mediator Pharmacogenomics: SNPs and Estrogen-Dependent Regulation of Inflammation. Journal of Nature and Science, 2017, 3, .	1.1	1
102	Pharmacometabolomics informs pharmacogenomics. Metabolomics, 2016, 12, 1.	3.0	43
103	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research, 2016, 76, 7012-7023.	0.9	47
104	Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open, 2016, 6, e010332.	1.9	32
105	Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?. Pediatric Blood and Cancer, 2016, 63, 2104-2111.	1.5	35
106	A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. Scientific Reports, 2016, 6, 37003.	3.3	9
107	Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercntile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Human Psychopharmacology, 2016, 31, 185-192.	1.5	60
108	Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. International Journal of Oncology, 2016, 49, 471-478.	3.3	32

#	ARTICLE	IF	CITATIONS
109	Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1531-1539.	2.4	10
110	Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation. <i>Molecular Endocrinology</i> , 2016, 30, 382-398.	3.7	27
111	Preemptive Pharmacogenomic Testing for Precision Medicine. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 438-445.	2.8	171
112	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	5.1	31
113	Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. <i>PLoS ONE</i> , 2015, 10, e0145176.	2.5	26
114	Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 141-149.	5.1	17
115	Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 59-66.	2.3	19
116	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. <i>Steroids</i> , 2015, 99, 32-38.	1.8	38
117	KnowEnG: a knowledge engine for genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1115-1119.	4.4	13
118	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. <i>Oncotarget</i> , 2015, 6, 7390-7407.	1.8	15
119	Electrophysiological Neuroimaging using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients. <i>Hospital Chronicles</i> , 2015, 10, 91-98.	1.0	4
120	Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics. <i>Studies in Health Technology and Informatics</i> , 2015, 210, 914-8.	0.3	3
121	Treatment Outcomes of Depression. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 313-317.	1.4	46
122	The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. <i>Nucleic Acids Research</i> , 2014, 42, e172-e172.	14.5	33
123	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. <i>Cancer Genetics</i> , 2014, 207, 19-30.	0.4	5
124	Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol. <i>Mayo Clinic Proceedings</i> , 2014, 89, 25-33.	3.0	250
125	Metformin Pharmacogenomics: Biomarkers to Mechanisms. <i>Diabetes</i> , 2014, 63, 2609-2610.	0.6	14
126	Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 373-383.	2.4	67



#	ARTICLE	IF	CITATIONS
127	Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. Journal of the National Cancer Institute, 2014, 106, .	6.3	4
128	Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET). Genome Medicine, 2013, 5, 7.	8.2	13
129	Natriuretic Peptide Receptor-3 Gene ( NPR3 ). Circulation: Cardiovascular Genetics, 2013, 6, 201-210.	5.1	12
130	TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression. Molecular Endocrinology, 2013, 27, 657-670.	3.7	49
131	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. Cancer Discovery, 2013, 3, 812-825.	9.4	61
132	Genome-wide association studies in pharmacogenomics. Pharmacogenetics and Genomics, 2013, 23, 383-394.	1.5	144
133	FKBP5 genetic variation. Pharmacogenetics and Genomics, 2013, 23, 156-166.	1.5	54
134	Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenetics and Genomics, 2013, 23, 242-248.	1.5	104
135	Pharmacogenomics and Patient Care: One Size Does Not Fit All. Science Translational Medicine, 2012, 4, 153ps18.	12.4	49
136	Human Liver Methionine Cycle: <i>MAT1A</i> and <i>GNMT</i> Gene Resequencing, Functional Genomics, and Hepatic Genotype-Phenotype Correlation. Drug Metabolism and Disposition, 2012, 40, 1984-1992.	3.3	16
137	Merging pharmacometabolomics with pharmacogenomics using ~1000 Genomes™ single-nucleotide polymorphism imputation. Pharmacogenetics and Genomics, 2012, 22, 247-253.	1.5	61
138	Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Research, 2012, 14, R41.	5.0	60
139	Mycophenolic acid response biomarkers: A cell line model system-based genome-wide screen. International Immunopharmacology, 2011, 11, 1057-1064.	3.8	10
140	Betaine-homocysteine methyltransferase: Human liver genotype-phenotype correlation. Molecular Genetics and Metabolism, 2011, 102, 126-133.	1.1	38
141	CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, 2011, 21, 1-9.	1.5	126
142	Genomics and Drug Response. New England Journal of Medicine, 2011, 364, 1144-1153.	27.0	552
143	Methionine Adenosyltransferase 2A/2B and Methylation: Gene Sequence Variation and Functional Genomics. Drug Metabolism and Disposition, 2011, 39, 2135-2147.	3.3	20
144	Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenetics and Genomics, 2010, 20, 401-405.	1.5	42

#	ARTICLE	IF	CITATIONS
145	Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach. BMC Genomics, 2010, 11, 357.	2.8	19
146	Thiopurine S-methyltransferase pharmacogenetics: Functional characterization of a novel rapidly degraded variant allozyme. Biochemical Pharmacology, 2010, 79, 1053-1061.	4.4	18
147	Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer. Cancer Research, 2010, 70, 3278-3286.	0.9	63
148	Ecto-5â€²-Nucleotidase and Thiopurine Cellular Circulation: Association with Cytotoxicity. Drug Metabolism and Disposition, 2010, 38, 2329-2338.	3.3	16
149	Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. Journal of Clinical Oncology, 2010, 28, 4674-4682.	1.6	196
150	Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation. Journal of Molecular and Cellular Cardiology, 2010, 49, 864-874.	1.9	24
151	CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system. Leukemia and Lymphoma, 2010, 51, 1315-1325.	1.3	15
152	Natriuretic Peptide Pharmacogenomics: Common Gene Sequence Variation and Functional Characterization of Membrane Metalloâ€²Endopeptidase (MME). FASEB Journal, 2010, 24, 756.1.	0.5	0
153	Human <i>S&amp;lt;/i&gt;</i> â€²adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization. Journal of Neurochemistry, 2009, 110, 1806-1817.	3.9	11
154	Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. JAMA - Journal of the American Medical Association, 2009, 302, 1429.	7.4	468
155	Catechol O-methyltransferase pharmacogenomics: human liver genotypeâ€²phenotype correlation and proximal promoter studies. Pharmacogenetics and Genomics, 2009, 19, 577-587.	1.5	11
156	Cytosolic 5â€²-nucleotidase III (NT5C3): gene sequence variation and functional genomics. Pharmacogenetics and Genomics, 2009, 19, 567-576.	1.5	29
157	Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers. PLoS ONE, 2009, 4, e7765.	2.5	75
158	PHARMACOGENETICS AND PHARMACOGENOMICS. , 2009, , 219-224.		1
159	Metabolomics: A Global Biochemical Approach to Drug Response and Disease. Annual Review of Pharmacology and Toxicology, 2008, 48, 653-683.	9.4	599
160	Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: Common gene sequence variation and functional characterization. Molecular Genetics and Metabolism, 2008, 94, 326-335.	1.1	59
161	Structural Basis of Substrate Recognition in Thiopurine <i>S&amp;lt;/i&gt;</i> -Methyltransferase. Biochemistry, 2008, 47, 6216-6225.	2.5	32
162	Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Human Molecular Genetics, 2008, 17, R174-R179.	2.9	53

#	ARTICLE	IF	CITATIONS
163	Glutathione <i>S</i> -Transferase P1: Gene Sequence Variation and Functional Genomic Studies. <i>Cancer Research</i> , 2008, 68, 4791-4801.	0.9	74
164	Human phenylethanolamine <i>N</i> -methyltransferase genetic polymorphisms and exercise-induced epinephrine release. <i>Physiological Genomics</i> , 2008, 33, 323-332.	2.3	11
165	Effect of Resveratrol on 17 $\beta$ -Estradiol Sulfation by Human Hepatic and Jejunal S9 and Recombinant Sulfotransferase 1E1. <i>Drug Metabolism and Disposition</i> , 2008, 36, 129-136.	3.3	30
166	Breast Cancer Risk Reduction and Membrane-Bound Catechol <i>O</i> -Methyltransferase Genetic Polymorphisms. <i>Cancer Research</i> , 2008, 68, 5997-6005.	0.9	38
167	Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 1083-1094.	1.5	27
168	Pharmacogenomics of Endocrine Therapy in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 630, 220-231.	1.6	20
169	Human SULT1A1 gene: copy number differences and functional implications. <i>Human Molecular Genetics</i> , 2007, 16, 463-470.	2.9	102
170	Human Hydroxysteroid Sulfotransferase SULT2B1 Pharmacogenomics: Gene Sequence Variation and Functional Genomics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 529-540.	2.5	29
171	Human 3 $\beta$ -hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 107, 88-99.	2.5	20
172	Glutathione <i>S</i> -Transferase T1 and M1: Gene Sequence Variation and Functional Genomics. <i>Clinical Cancer Research</i> , 2007, 13, 7207-7216.	7.0	69
173	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 113-121.	2.5	520
174	Pharmacogenomics: Challenges and Opportunities. <i>Annals of Internal Medicine</i> , 2006, 145, 749.	3.9	228
175	Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. <i>Annual Review of Genomics and Human Genetics</i> , 2006, 7, 223-245.	6.2	203
176	Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 265-277.	1.5	58
177	Pharmacogenomics: Catechol O-Methyltransferase to Thiopurine S-Methyltransferase. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 537-559.	3.3	51
178	Human Arsenic Methyltransferase (AS3MT) Pharmacogenetics. <i>Journal of Biological Chemistry</i> , 2006, 281, 7364-7373.	3.4	119
179	Methylenetetrahydrofolate Reductase Haplotype Tag Single-Nucleotide Polymorphisms and Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2322-2324.	2.5	10
180	GLUTATHIONE S-TRANSFERASE OMEGA 1 AND OMEGA 2 PHARMACOGENOMICS. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1237-1246.	3.3	77

#	ARTICLE	IF	CITATIONS
181	Pharmacogenomics: Bench to Bedside. Focus (American Psychiatric Publishing), 2006, 4, 431-441.	0.8	3
182	Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenetics and Genomics, 2005, 15, 801-815.	1.5	127
183	Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. Journal of Neurochemistry, 2005, 95, 1766-1776.	3.9	46
184	Human Aromatase: Gene Resequencing and Functional Genomics. Cancer Research, 2005, 65, 11071-11082.	0.9	185
185	Human thiopurine S-methyltransferase pharmacogenetics: Variant allozyme misfolding and aggresome formation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9394-9399.	7.1	103
186	CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. Journal of the National Cancer Institute, 2005, 97, 30-39.	6.3	867
187	Sulfate Conjugation. , 2005, , 61-78.		1
188	Pharmacogenomics: Bench to bedside. Discovery Medicine, 2005, 5, 30-6.	0.5	10
189	Cat Red Blood Cell Thiopurine S-Methyltransferase: Companion Animal Pharmacogenetics. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 617-626.	2.5	17
190	Pharmacogenomics: bench to bedside. Nature Reviews Drug Discovery, 2004, 3, 739-748.	46.4	293
191	Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity*1. Clinical Pharmacology and Therapeutics, 2004, 75, 253-258.	4.7	40
192	Primer on Medical Genomics: Part XII: Pharmacogenomicsâ€™ General Principles With Cancer as a Model. Mayo Clinic Proceedings, 2004, 79, 376-384.	3.0	29
193	Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochemical and Biophysical Research Communications, 2004, 321, 870-878.	2.1	61
194	Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system. Biochemical and Biophysical Research Communications, 2004, 325, 426-433.	2.1	15
195	Thiopurine Methyltransferase Activity in Red Blood Cells of Dogs. Journal of Veterinary Internal Medicine, 2004, 18, 214-218.	1.6	21
196	Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. British Journal of Pharmacology, 2003, 139, 1373-1382.	5.4	87
197	Inheritance and Drug Response. New England Journal of Medicine, 2003, 348, 529-537.	27.0	961
198	Intensification of Mercaptopurine/Methotrexate Maintenance Chemotherapy May Increase the Risk of Relapse for Some Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2003, 21, 1332-1339.	1.6	106

#	ARTICLE	IF	CITATIONS
199	Pharmacogenomics and reducing the frequency of adverse drug events. <i>Pharmacogenomics</i> , 2003, 4, 1-4.	1.3	40
200	Thiopurine S-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 555-564.	5.7	90
201	Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. <i>Journal of Neurochemistry</i> , 2003, 87, 809-819.	3.9	55
202	Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 555-64.	5.7	33
203	Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1123-1128.	3.3	18
204	Canine red blood cell thiopurine S-methyltransferase. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 713-724.	5.7	21
205	Catecholesterogen Sulfation: Possible Role in Carcinogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 402-408.	2.1	100
206	Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5' flanking region single nucleotide polymorphism (SNP). <i>Biochemical Pharmacology</i> , 2002, 64, 699-710.	4.4	37
207	The Gordon Wilson Lecture. The Mayo model: one path to an academic medical center. <i>Transactions of the American Clinical and Climatological Association</i> , 2002, 113, 91-103; discussion 103-6.	0.5	1
208	Theoretical 3D Model of Histamine N-Methyltransferase: Insights into the Effects of a Genetic Polymorphism on Enzymatic Activity and Thermal Stability. <i>Biochemical and Biophysical Research Communications</i> , 2001, 287, 204-208.	2.1	24
209	Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 747-756.	5.7	52
210	Chapter 6: Estrogen Metabolism by Conjugation. <i>Journal of the National Cancer Institute Monographs</i> , 2000, 2000, 113-124.	2.1	239
211	Severe 6-Thioguanine-induced Marrow Aplasia in a Child With Acute Lymphoblastic Leukemia and Inherited Thiopurine Methyltransferase Deficiency. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 441-445.	1.3	42
212	The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2000, 23, 143-148.	0.7	35
213	Histamine N-methyltransferase functional polymorphism: Lack of association with schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 404-406.	2.4	20
214	Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 210-219.	4.7	111
215	Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 261-266.	5.7	89
216	METHYLATION PHARMACOGENETICS: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase. <i>Annual Review of Pharmacology and Toxicology</i> , 1999, 39, 19-52.	9.4	513

#	ARTICLE	IF	CITATIONS
217	Human phenol sulfotransferases SULT1A2 and SULT1A1. <i>Biochemical Pharmacology</i> , 1999, 58, 605-616.	4.4	180
218	Human Indolethylamine N-Methyltransferase: cDNA Cloning and Expression, Gene Cloning, and Chromosomal Localization. <i>Genomics</i> , 1999, 61, 285-297.	2.9	62
219	Human nicotinamide N-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 307-316.	5.7	24
220	Mouse Nicotinamide N-Methyltransferase Gene: Molecular Cloning, Structural Characterization, and Chromosomal Localization. <i>DNA and Cell Biology</i> , 1998, 17, 659-667.	1.9	5
221	Human Histamine N-Methyltransferase Pharmacogenetics: Common Genetic Polymorphisms that Alter Activity. <i>Molecular Pharmacology</i> , 1998, 53, 708-717.	2.3	135
222	Mouse Liver Nicotinamide N-Methyltransferase. <i>Biochemical Pharmacology</i> , 1997, 54, 1139-1149.	4.4	33
223	Phenol Sulfotransferase Pharmacogenetics in Humans: Association of Common SULT1A1 Alleles with TS PST Phenotype. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 298-304.	2.1	285
224	Sulfotransferase molecular biology: cDNAs and genes. <i>FASEB Journal</i> , 1997, 11, 3-14.	0.5	398
225	Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 464-475.	4.7	148
226	Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 60-73.	4.7	384
227	Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common Polymorphism. <i>DNA and Cell Biology</i> , 1996, 15, 17-30.	1.9	309
228	Human Histamine N-Methyltransferase Gene: Structural Characterization and Chromosomal Localization. <i>Biochemical and Biophysical Research Communications</i> , 1996, 219, 548-554.	2.1	36
229	Long PCR: Selective Suppression by Restriction Endonuclease Digestion. <i>BioTechniques</i> , 1996, 21, 764-766.	1.8	3
230	Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 243-250.	5.7	1,681
231	Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 43-53.	5.7	21
232	Human sulfotransferase pharmacogenetics: STP2 gene, structural characterization and chromosomal localization. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 216-216.	4.7	1
233	Segregation analysis of human red blood cell thiopurine methyltransferase activity. <i>Genetic Epidemiology</i> , 1995, 12, 1-11.	1.3	49
234	Human Estrogen Sulfotransferase Gene (STE): Cloning, Structure, and Chromosomal Localization. <i>Genomics</i> , 1995, 29, 16-23.	2.9	42

#	ARTICLE	IF	CITATIONS
235	Human NicotinamideN-Methyltransferase Gene: Molecular Cloning, Structural Characterization and Chromosomal Localization. <i>Genomics</i> , 1995, 29, 555-561.	2.9	48
236	Sulfation pharmacogenetics in humans. <i>Chemico-Biological Interactions</i> , 1994, 92, 233-246.	4.0	45
237	Purine substrates for human thiopurine methyltransferase. <i>Biochemical Pharmacology</i> , 1994, 48, 2135-2138.	4.4	55
238	Genetic segregation analysis of red blood cell (RBC) histamineN-methyltransferase (HNMT) activity. <i>Genetic Epidemiology</i> , 1993, 10, 123-131.	1.3	23
239	HistamineN-methyltransferase: Inhibition by monoamine oxidase inhibitors. <i>Agents and Actions</i> , 1993, 40, 1-10.	0.7	13
240	Human liver thiopurine methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1992, 2, 148-159.	5.7	201
241	Human kidney thiopurine methyltransferase. <i>Biochemical Pharmacology</i> , 1992, 44, 775-785.	4.4	18
242	Human liver xanthine oxidase: Nature and extent of individual variation. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 663-672.	4.7	109
243	Inheritance of human plasma dopamine- $\beta$ -hydroxylase thermal stability. <i>Genetic Epidemiology</i> , 1991, 8, 237-251.	1.3	3
244	Human liver catechol-O-methyltransferase pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 381-389.	4.7	226
245	Major gene polymorphism for human erythrocyte (RBC) thiol methyltransferase (TMT). <i>Genetic Epidemiology</i> , 1989, 6, 651-662.	1.3	17
246	Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 149-154.	4.7	583
247	Sulfation pharmacogenetics: Correlation of human platelet and small intestinal phenol sulfotransferase. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 501-509.	4.7	27
248	Methyltransferase pharmacogenetics. , 1989, 43, 77-90.		91
249	Inheritance of human platelet thermolabile phenol sulfotransferase (TL PST) activity. <i>Genetic Epidemiology</i> , 1988, 5, 1-15.	1.3	51
250	Pharmacogenetics of N-methylation: Heritability of human erythrocyte histamine N-methyltransferase activity. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 256-262.	4.7	44
251	Pharmacogenetics of methyl conjugation and thiopurine drug toxicity. <i>BioEssays</i> , 1987, 7, 78-82.	2.5	6
252	The therapeutic revolution. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 481-484.	4.7	56

#	ARTICLE	IF	CITATIONS
253	Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 18-25.	4.7	334
254	Analysis of the distribution of erythrocyte sodium lithium countertransport in a sample representative of the general population. <i>Genetic Epidemiology</i> , 1986, 3, 365-378.	1.3	72
255	Sulfate and methyl dopa metabolism: Metabolite patterns and platelet phenol sulfotransferase activity. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 308-315.	4.7	29
256	Thiopurine methyltransferase: mouse kidney and liver assay conditions, biochemical properties and strain variation. <i>Biochemical Pharmacology</i> , 1985, 34, 3823-3830.	4.4	20
257	Human erythrocyte histamine N-methyltransferase: radiochemical microassay and biochemical properties. <i>Clinica Chimica Acta</i> , 1985, 149, 237-251.	1.1	29
258	Major gene model for the inheritance of catechol-o-methyltransferase activity in five large families. <i>American Journal of Medical Genetics Part A</i> , 1984, 19, 315-323.	2.4	23
259	Linkage relationships between a major gene for catechol-o-methyltransferase activity and 25 polymorphic marker systems. <i>American Journal of Medical Genetics Part A</i> , 1984, 19, 525-532.	2.4	13
260	Human platelet phenol sulfotransferase: Familial variation in thermal stability of the TS form. <i>Biochemical Genetics</i> , 1984, 22, 997-1014.	1.7	64
261	Erythrocyte Catechol-O-Methyltransferase, Platelet Monoamine Oxidase, and Platelet Phenol Sulfotransferase Activities in Patients with Prolactin Secreting Pituitary Adenomas*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 59, 1207-1210.	3.6	3
262	Thermolabile and thermostable human platelet phenol sulfotransferase. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1983, 324, 140-147.	3.0	106
263	Human kidney thiopurine methyltransferase purification and biochemical properties. <i>Biochemical Pharmacology</i> , 1983, 32, 819-826.	4.4	128
264	Thiol methylation pharmacogenetics: Heritability of human erythrocyte thiol methyltransferase activity. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 521-528.	4.7	37
265	Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity. <i>Biochemical Genetics</i> , 1982, 20, 637-658.	1.7	100
266	Genetics of red cell COMT activity: Analysis of thermal stability and family data. <i>American Journal of Medical Genetics Part A</i> , 1981, 10, 279-290.	2.4	120
267	Catechol-O-methyltransferase biochemical genetics: Human lymphocyte enzyme. <i>Biochemical Genetics</i> , 1981, 19, 1037-1053.	1.7	40
268	Monogenic inheritance of catechol-O-methyltransferase activity in the rat—biochemical and genetic studies. <i>Biochemical Pharmacology</i> , 1979, 28, 1239-1247.	4.4	26
269	Human erythrocyte thiol methyltransferase: Radiochemical microassay and biochemical properties. <i>Clinica Chimica Acta</i> , 1979, 97, 59-71.	1.1	60
270	Human erythrocyte catechol-o-methyltransferase: Correlation with lung and kidney activity. <i>Life Sciences</i> , 1978, 22, 625-630.	4.3	56



#	ARTICLE	IF	CITATIONS
271	Prolonged hypouricemia associated with acute chlorprothixene ingestion. <i>Arthritis and Rheumatism</i> , 1975, 18, 739-742.	6.7	9
272	Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. <i>Nature</i> , 1974, 252, 490-491.	27.8	62
273	Serum Dopamine-Beta-Hydroxylase Activity. <i>Circulation Research</i> , 1971, 28, 307-315.	4.5	339